#USA #Cardiff-by-the-Sea #Field Medical #FieldForce #cardiac ablation

Field Medical Secures $35 Million Series B Funding to Revolutionize Cardiac Care

Field Medical, Inc. has reached a significant milestone in the advancement of cardiac care by finalizing an oversubscribed Series B financing round of $35 million. This funding is pivotal for enhancing the development of its cutting-edge FieldForce™ Pulsed Field Ablation (PFA) platform. The announcement, made on July 1, 2025, reveals co-leaders of this financing round, BioStar Capital and Cue Growth, alongside participation from existing strategic investors.

The funds will enable Field Medical to kick-start its pivotal VERITAS clinical trial and further develop the FieldForce Ablation System, which aims to make marked improvements in the treatment landscape for ventricular tachycardia (VT). Notably, the Series B funding increases the total raised by the company to $75 million, showcasing its commitment to pioneering innovations in the field of electrophysiology.

Dr. Steven Mickelsen, founder and CEO of Field Medical, highlighted that VT remains one of the significant challenges within electrophysiology, with many physicians lacking proper tools for effective treatment. He equated the current landscape of VT treatment to the early days of atrial fibrillation (AF) market development, indicating a strong clinical demand for technology that meets the needs of patients more effectively.

Field Medical’s ability to attract significant investment is helped by promising pilot data shared at the 2025 Heart Rhythm Society meeting. The company emphasizes that its next-generation therapy is built for speed and precision in treatment, representing a transformative opportunity for high-risk patients suffering from VT.

Strategic Board Leadership Updates

In conjunction with the financing success, Field Medical has also made notable changes to its Board of Directors to align with its robust growth strategy. Key appointments include:

• - Dr. Steven Mickelsen as CEO, who is already celebrated as an inventor of PFA technologies like FARAPULSE™ and FieldForce™.
• - Mark Wisniewski, CFO of Enterra Medical, who will serve as the chairperson of the Field Medical board, bringing extensive operational expertise in the medtech industry.
• - Marlou Janssen, an executive with a wealth of experience in cardiology and medtech, joining as a board member, whose previous role includes president of Biotronik U.S.
• - Alexei Mlodinow, MD, whose serial entrepreneurship and medical background will further strengthen the board’s diverse expertise.
• - Ben Cannon, founding partner of Cue Growth, providing insights into scaling growth-stage companies effectively.

About Field Medical® Inc.

Founded in 2022, Field Medical is at the forefront of advancing pulsed field ablation technologies specifically tailored to treat complex cardiac arrhythmias. The FieldForce™ Ablation System combines an innovative catheter design with proprietary FieldBending™ energy technology, designed to facilitate rapid and targeted ablation treatments. The company gained vital recognition in 2024 through its Breakthrough Device Designation and participation in the FDA TAP Pilot Program, underscoring its commitment to transforming VT management.

For those eager to delve deeper into the clinical implications of their technology and learn about the ongoing struggles in VT treatment, Field Medical recently participated in the Heart Rhythm 2025 Satellite Symposium. Additional information and updates can be found through their official website at www.fieldmedicalinc.com, as well as via their social media platforms.

As the company continues to expand its reach and innovate within the medical technology space, Field Medical stands poised to redefine standards of care and enhance the quality of life for patients battling ventricular tachycardia.

Media Contact:
Holly Windler
[Email Address Placeholder]